Journal of oncology research and therapy最新文献_第3页

Updates on the Importance of CD200:CD200R Checkpoint Blockade in Solid Tumors and B cell Malignancies CD200:CD200R检查点阻断在实体瘤和B细胞恶性肿瘤中的重要性的最新进展

Journal of oncology research and therapy Pub Date : 2023-10-03 DOI: 10.29011/2574-710x.10185

{"title":"Updates on the Importance of CD200:CD200R Checkpoint Blockade in Solid Tumors and B cell Malignancies","authors":"","doi":"10.29011/2574-710x.10185","DOIUrl":"https://doi.org/10.29011/2574-710x.10185","url":null,"abstract":"The last several years have seen the introduction into clinical medicine of a family of reagents directed towards so-called “checkpoint inhibitors”, which act at gateways in a developing immune response to regulate unwanted and/or harmful self-directed activation responses. The molecules involved at such gateways generally belong to an extended immunoglobulin supergene family, and contribute inhibitory signals to dampen over-exuberant responses. They include, but are not limited to, molecules of the CD28/cytotoxic T-lymphocyte antigen-4 (CTLA-4):B7.1/B7.2 receptor/ligand family; PD-1 and PDL-1; CD200 and CD200R; TIGIT and VISTA and their respective ligands (VSIG-3/IGSF11, Nectin), all of which are presumed to play a physiological role in maintaining natural self-tolerance. In the field of cancer immunotherapy, where the ultimate clinical goal is to improve immuno-targeting of cancer cells, triggering these checkpoint inhibitory signaling pathways, has the potential to thwart effective tumor immunity. This in turn has led to the characterization and application of multiple reagents, including antibodies and other designed inhibitory molecules, which can act as checkpoint blockade agents. Such reagents have had a dramatic effect on human cancer treatment, with marked success for anti-CTLA-4 and PD-1 in particular in clinical trials. This review elaborates on the promise on other more under-appreciated target molecules for checkpoint blockade in human B cell malignancies and solid tumors, particularly CD200:CD200R, and describes both the background, and newer studies, which highlight the potential importance of targeting the CD200:CD200R dyad in cancer immunobiology/therapy.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"45 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135746053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Efficacy and Safety of Head and Neck Cancer Treatment using Photodynamic and Ultrasound Therapy: A Systematic Review 光动力和超声治疗头颈部肿瘤的疗效和安全性:系统综述

Journal of oncology research and therapy Pub Date : 2023-08-28 DOI: 10.29011/2574-710x.10184

引用次数: 0

Beyond Overall Survival: The Value of Oncology- Relevant Endpoints in HTA Body / Payer Decision-Making 超越总生存期:肿瘤相关终点在HTA机体/支付者决策中的价值

Journal of oncology research and therapy Pub Date : 2023-08-14 DOI: 10.29011/2574-710x.10181

Iñaki Gutiérrez-Ibarluzea, N. Bolaños, Jan Geissler, Giovanni Gorgoni, Tara Lumley, Joseph Mikhael, Tamara Milagre, H. Poppel, L.E.K Consultant, Consulting

引用次数: 0

Expressions of H3K9me2 and E-cadherin Correlate with Cervical Cancer Invasiveness H3K9me2和E-cadherin的表达与宫颈癌侵袭性的关系

Journal of oncology research and therapy Pub Date : 2023-08-07 DOI: 10.29011/2574-710x.10179

Ruey-Jien Chen, Chia-Hung Chou, Chia-Tung Shun, Wen-Fen Wen, Men-Luh Yen, Shee-Uan Chen

引用次数: 0

Sentinel Lymph Node Biopsy in Breast Cancer: Past, Present, and Future 乳腺癌前哨淋巴结活检:过去，现在和未来

Journal of oncology research and therapy Pub Date : 2023-07-29 DOI: 10.29011/2574-710x.10178

引用次数: 1

Pneumomediastinum Secondary to a Major Response to Nivolumab in Mesothelioma 间皮瘤患者对纳武单抗的主要反应继发于纵隔气肿

Journal of oncology research and therapy Pub Date : 2023-07-24 DOI: 10.29011/2574-710x.10176

M. S. Moyano, D. G. Antonio

{"title":"Pneumomediastinum Secondary to a Major Response to Nivolumab in Mesothelioma","authors":"M. S. Moyano, D. G. Antonio","doi":"10.29011/2574-710x.10176","DOIUrl":"https://doi.org/10.29011/2574-710x.10176","url":null,"abstract":"Introduction: Malignant pleural mesothelioma (MPM) is a rare entity associated with chronic asbestos exposure. Second-line immunotherapy (IT) treatment is associated with very limited benefit, although in selected patients, durable partial responses have been reported. Material and methods: This case describes the evolution of a patient with MPM undergoing palliative pleurodesis at diagnosis who received second-line Nivolumab monotherapy at the Department of Medical Oncology of the Hospital Universitario Infanta Sofia and follow-up at the Department of Thoracic Surgery of the Hospital Universitario Puerta de Hierro. Results: We describe the case of an 83-year-old patient diagnosed with MPM who, after palliative pleurodesis at diagnosis and 4 cycles of platinum-based chemotherapy, had an excellent response to Nivolumab monotherapy. As a consequence of this good response, he presented a pneumomediastinum and subcutaneous emphysema without pneumothorax when a mediastinal-pleural communication developed. Management was conservative and the patient, six months after discontinuation of treatment, is in response with complete resolution of this complication. Conclusion: This case shows a dramatic response to second-line Nivolumab in advanced MPM with the development of a pneumomediastinum as a resultant complication. This finding has not been previously described in the literature.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75293246","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Neurological Safety Profile in the Use of Checkpoint Inhibitors: A Real-World Evidence Approach Based on Pharmacovigilance Data 使用检查点抑制剂的神经系统安全性评估:基于药物警戒数据的真实世界证据方法

Journal of oncology research and therapy Pub Date : 2023-07-24 DOI: 10.29011/2574-710x.10177

A. Abrahao, Tenorio PHM², M. Rodrigues, Osvaldo J. M. do Nascimento¹, O. Nascimento

{"title":"Evaluation of Neurological Safety Profile in the Use of Checkpoint Inhibitors: A Real-World Evidence Approach Based on Pharmacovigilance Data","authors":"A. Abrahao, Tenorio PHM², M. Rodrigues, Osvaldo J. M. do Nascimento¹, O. Nascimento","doi":"10.29011/2574-710x.10177","DOIUrl":"https://doi.org/10.29011/2574-710x.10177","url":null,"abstract":"The use of immunotherapies based on the concept of checkpoint inhibitors is increasingly becoming a medical practice in oncology. These therapies target some specific factors, inhibiting them, blocking them to stop the multiplication of these altered cells and consequently the tumor. This study focused on the neurological safety profile of the most prescribed checkpoint inhibitors and traced a correlation between the use of these agents and the increase in neurological adverse events in the main indications. Examining pharmacovigilance databases and medication sales, the analysis found a correlation between reported neurological adverse events and medication usage. As the total number of adverse events increased, the number of neurological adverse events also rose linearly, emphasizing the importance of monitoring potential neurological effects. For the analysis of adverse event data, the databases of FDA (FAERS) and EMA (VigiAccess) were consulted, while sales data between 2018 and 2022 were extracted from the IQVIA Analytics databases. Among the studied checkpoint inhibitors (pembrolizumab, ipilimumab, nivolumab, atezolizumab, and avelumab), pembrolizumab had the lowest ratio of reported adverse events, suggesting a relatively safer profile.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"12 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87297971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Distant Metastasis to Genital Organs in Infiltrating Ductal Carcinoma of the Breast in a Young Patient 年轻乳腺浸润性导管癌远处转移至生殖器官1例

Journal of oncology research and therapy Pub Date : 2023-06-26 DOI: 10.29011/2574-710x.10174

引用次数: 0

Health Literacy and Oral Oncology study on the HPV Risk Factor in a Portuguese University 健康素养和口腔肿瘤对葡萄牙大学HPV危险因素的研究

Journal of oncology research and therapy Pub Date : 2023-06-23 DOI: 10.29011/2574-710x.10173

Augusta Silveira, P. Ferreira, M. Vieira, Samuel Andrade, Clara Mancelos, T. Sequeira

引用次数: 0

SIRT2 Suppression Increases Responsiveness of Glioma Cells to Radiation Treatment via FoxO3a Inhibition SIRT2抑制通过FoxO3a抑制提高胶质瘤细胞对放射治疗的反应性

Journal of oncology research and therapy Pub Date : 2023-05-23 DOI: 10.29011/2574-710x.10171

Zhihan Wang, Jianyi Zhao, Wenrui Zhang, Keman Liao, Hao Xu, Zilong Wei, Li Ren

{"title":"SIRT2 Suppression Increases Responsiveness of Glioma Cells to Radiation Treatment via FoxO3a Inhibition","authors":"Zhihan Wang, Jianyi Zhao, Wenrui Zhang, Keman Liao, Hao Xu, Zilong Wei, Li Ren","doi":"10.29011/2574-710x.10171","DOIUrl":"https://doi.org/10.29011/2574-710x.10171","url":null,"abstract":"Due to the resistance to radiotherapy, the prognosis of patients with glioblastoma multiforme (GBM) is poor despite standard treatment. Forkhead Box O3 (FoxO3a) is reported to mediate multiple pathological processes involved in proliferation, apoptosis, and DNA repair processes, and associated with poor prognosis of GBM. Further work is required to explore the role of FoxO3a in GBM radioresistance. RT-qPCR indicated that FoxO3a was significantly up-regulated in GBM cells in response to radiation. Knockdown of FoxO3a enhances the responsiveness of GBM cells to radiotherapy. After radiation stimulation, the clonogenic capacity of the cells with FoxO3a knockdown (KD) was much weaker than that of the normal control group (NC), while the degree of DNA damage detected by the comet assay was significantly higher in the cells with FoxO3a knockdown. Moreover, combining recent research, we demonstrated that suppression of SIRT2 down-regulated FoxO3a with radiation therapy by Western Blot. DNA damage assay and comet assay indicated that the degree of DNA damage increased in the cells of SIRT2 knockdown compared to the normal control (NC). The study indicated that suppression of SIRT2 increased the sensitivity of GBM cells to radiotherapy via FoxO3a inhibition and provided a novel idea for overcoming radioresistance in GBM.","PeriodicalId":73876,"journal":{"name":"Journal of oncology research and therapy","volume":"21 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2023-05-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75699966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0